Conversations on Twitter :
-
What is the long-term potential of Gilead in the Hep C market? Initial debate forming…
Includes insider @adamfeuerstein - More discussion on the hot Hep C field can be found here and here.
@FierceBiotech: CIRM favors teamwork with $150M in new stem cell grants. Story | Follow @FierceBiotech
@JohnCFierce: Deja vu: Dimebon (remember it?) promising in mouse study for Alzheimer's. Scientists want to go back, try again. Release | Follow @JohnCFierce
@RyanMFierce: Biotech VC deals abound this week: Ultragenyx nailed down $15M, and now Mersana says it's found $27M more with help from deep pockets at NEA. | Follow @RyanMFierce
> KV Pharma may be threatening to file bankruptcy as compounding pharmacies continues to undercut its new drug to prevent premature births, but CEO Greg Divis still warranted a big pay hike. Story
> Remember Dimebon, the experimental Alzheimer's drug that flunked a series of expensive late-stage studies and cost Pfizer a fortune? Scientists at Mt. Sinai say they've put it through mouse tests again--where it proved positive. Now they want to try again and see whether the once-promising compound could work for a certain population. Release
> Astellas Pharma inked a research pact with the Tokyo Institute of Technology in which they will search for new drugs to treat diseases caused by protozoan parasites, such as chagas disease. Story
> CMC Biologics has acquired Xoma's large-scale biologics manufacturing operations in Berkeley, CA. Release
> Australia's Novogen is merging into the U.S.-based devices company Kai Medical. It's selling its glucan tech to TR Therapeutics. Story
Pharma News
@FiercePharma: WSJ's list of 25 Best CFOs includes 3 drug company execs: Biogen, Allergan, Perrigo. List | Follow @FiercePharma
> Pfizer nears animal health IPO as cost-cutting boosts profits. Story
> Glaxo changes the guard at newly bought HGS. News
> Dendreon to slash 600 more jobs as Provenge sales lag. Article
> FDA nixes new gout use for Regeneron's Arcalyst. Item
@FierceMedDev: Italy's DiaSorin Group signed a Dx expansion deal with Trivitron for the Indian market. Asian expansion continues. Release | Follow @FierceMedDev
@MarkHFierce: 23andMe will seek FDA 510(k) clearance for its new personalized DNA test, the company disclosed. Release | Follow @MarkHFierce
@DamianFierce: Looking to boost its flagging CRM business, Boston Sci snagged CE marks for two MRI-friendly pacemakers. More | Follow @DamianFierce
> Medtronic nabs 510(k) for combination surgical device. Item
> Teleflex hit with Class I recall of venous catheter. Story
Biotech Research News
> Another shot at treating Alzheimer's with Dimebon? Article
> 17 universities win NIH cash for tissue chip/drug safety testing. News
> CIRM favors teamwork with $150M in new stem cell grants. More
Pharma Manufacturing News
@EricPFierce: It is out with the old and with the new at HGS now that GSK is in charge. More | Follow @EricPFierce
> Plant's IT mess nearly kills AZ growth in new markets. News
> Drug pricing figures into McKesson settlement, earnings. Article
And Finally… Scientists used stem cells to regrow craniofacial tissues in the first human study of its kind. Release